Sol-Gel Technologies

SLGL

Market cap $170M

60.85 USD

-2.65

4.17%

At close Updated Jan 29, 4:00 PM EST

1 day

-4.17%

5 days

13.48%

1 month

36.62%

3 months

64.46%

6 months

407.08%

Year to date

44.37%

1 year

651.23%

5 years

-37.46%

10 years

-55.39%

About: Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Employees: 34

Healthcare Biotechnology